HIGHLIGHTS
- who: Hematology and collaborators from the Nantes/StHerblain , France have published the Article: Hematology Reviews 2009; volume 1:exxxx, in the Journal: (JOURNAL)
- what: In younger patients, post-ASCT maintenance therapy with thalidomide appears to increase tumor burden reduction further, which translates in prolonged PFS.
- how: In the French study by Barlogie et_al patients with del13 apparently did not benefit from thalidomide maintenance but at the time of this trial other abnormalities that are frequently associated with del(13) such as t(414) or 17p del were not routinely studied .
- future . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.